Benoxathian is an α1-adrenergic receptor antagonist.[1] It was studied in animals for its antihypertensive (blood pressure lowering) effects in the 1980s.[2]
Names | |
---|---|
IUPAC name
N-(2,3-Dihydro-1,4-benzoxathiin-2-ylmethyl)-2-(2,6-dimethoxyphenoxy)ethanamine
| |
Identifiers | |
3D model (JSmol)
|
|
ChemSpider | |
PubChem CID
|
|
CompTox Dashboard (EPA)
|
|
| |
| |
Properties | |
C19H23NO4S | |
Molar mass | 361.46 g·mol−1 |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
|
References
edit- ^ Nagayasu, K; Kitaichi, M; Nishitani, N; Asaoka, N; Shirakawa, H; Nakagawa, T; Kaneko, S (2013). "Chronic effects of antidepressants on serotonin release in rat raphe slice cultures: High potency of milnacipran in the augmentation of serotonin release". The International Journal of Neuropsychopharmacology. 16 (10): 2295–306. doi:10.1017/S1461145713000771. PMID 23920436.
- ^ Massi, M.; Venturi, F.; Brasili, L.; Melchiorre, C. (1986). "Hypotensive effect in dogs and rats of intravenous injections of the alpha 1-adrenoreceptor antagonist benoxathian". Pharmacological Research Communications. 18 (9): 813–829. doi:10.1016/0031-6989(86)90132-3. PMID 2879293.